These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Trials of new antiarrhythmic drugs for maintenance of sinus rhythm in patients with atrial fibrillation. Singh S J Interv Card Electrophysiol; 2004; 10 Suppl 1():71-6. PubMed ID: 14739742 [TBL] [Abstract][Full Text] [Related]
5. New horizons in antiarrhythmic therapy: will novel agents overcome current deficits? Conway E; Musco S; Kowey PR Am J Cardiol; 2008 Sep; 102(6A):12H-19H. PubMed ID: 18790110 [TBL] [Abstract][Full Text] [Related]
6. Medical management of atrial fibrillation: state of the art. Camm J J Cardiovasc Electrophysiol; 2006 Sep; 17 Suppl 2():S2-6. PubMed ID: 16939435 [TBL] [Abstract][Full Text] [Related]
13. Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm. Pritchett EL; Kowey P; Connolly S; Page RL; Kerr C; Wilkinson WE; Am Heart J; 2006 May; 151(5):1043-9. PubMed ID: 16644334 [TBL] [Abstract][Full Text] [Related]
14. Azimilide vs. placebo and sotalol for persistent atrial fibrillation: the A-COMET-II (Azimilide-CardiOversion MaintEnance Trial-II) trial. Lombardi F; Borggrefe M; Ruzyllo W; Lüderitz B; Eur Heart J; 2006 Sep; 27(18):2224-31. PubMed ID: 16935870 [TBL] [Abstract][Full Text] [Related]
15. Azimilide for atrial fibrillation: clinical trial results and implications. Pritchett EL; Marcello SR Card Electrophysiol Rev; 2003 Sep; 7(3):215-9. PubMed ID: 14739716 [TBL] [Abstract][Full Text] [Related]
16. Atrial fibrillation: emerging possibilities for drug treatment: an overview of current opportunities and recent developments. Papp JG; Singh BN J Cardiovasc Pharmacol Ther; 2003 Jun; 8 Suppl 1():S1-3. PubMed ID: 12746746 [No Abstract] [Full Text] [Related]
17. Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide. Wang J; Feng J; Nattel S Circulation; 1994 Oct; 90(4):2032-40. PubMed ID: 7923691 [TBL] [Abstract][Full Text] [Related]
18. New advances in class III antiarrhythmic drug therapy. Sager PT Curr Opin Cardiol; 2000 Jan; 15(1):41-53. PubMed ID: 10666660 [TBL] [Abstract][Full Text] [Related]
19. Conversion of atrial fibrillation by the experimental antiarrhythmic drug tedisamil in two canine models. Fischbach PS; Barrett TD; Goyal R; Tran BC; Syed ZA; Hennan JK; Lucchesi BR J Cardiovasc Electrophysiol; 2001 Oct; 12(10):1138-44. PubMed ID: 11699522 [TBL] [Abstract][Full Text] [Related]
20. [Basic mechanisms of the new antiarrhythmic drugs in atrial fibrillation]. Filgueiras-Rama D; Castrejón S; Calvo C; Estrada A; Doiny D; Ortega M; Berenfeld O; Merino JL; Jalife J Arch Cardiol Mex; 2012; 82(2):139-52. PubMed ID: 22735655 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]